Chugai and Gero Join Forces on Aging Disease Therapies

Chugai Pharmaceutical Co., Ltd. and Singapore-based biotechnology firm Gero PTE. LTD. Gero has announced a joint research and license agreement. This agreement aims to develop new treatments for age-related diseases.

Chugai will use its unique antibody engineering technologies in this collaboration. They want to make new antibody drugs that target disease mechanisms identified by Gero. Gero’s AI platform finds these targets by analyzing big human datasets. Gero gives Chugai exclusive global rights. They can research, develop, manufacture, and sell antibody drugs from these discoveries.

The financial terms involve an upfront payment to Gero. There are also milestone payments that could reach about $250 million. These payments depend on meeting certain development and commercial goals. Royalties on future product sales will also be paid by Chugai.

こちらもお読みください： アルファ・フュージョン社とCuradh MTR社がアスタチン211製剤で提携

Dr. Osamu Okuda, President and CEO of Chugai, highlighted how key partnerships help the company innovate. He said, “Working with top global partners is key to our world-class drug discovery goal in our TOP I 2030 strategy.” This partnership will combine Gero’s discovery platform with Chugai’s development technologies to push innovation ahead.”

Peter Fedichev, CEO of Gero, said, “Our AI platform finds key targets for age-related diseases and aging.” This partnership with Chugai helps us turn insights into therapies. Our goal is to restore lost function.”

Alex Kadet, Chief Business Officer at Gero, said, “We’re excited to team up with 中外製薬. Together, we will blend data-driven target discovery with advanced therapeutic design.” We aim to create top-notch treatments for the rising number of people with age-related conditions.”